Authors

Han Zhang1, Hongxia He2, Yu Chen3, *

Departments

1Department of Respiratory Medicine, the Second Clinical Medical College, Yangtze University, Jingzhou 434200, Hubei, China - 2Department of Respiratory and Critical Care Medicine, the First People’s Hospital of Jingmen, Jingmen 448000, Hubei, China - 3Department of Infectious Diseases, the First People’s Hospital of Jingmen, Jingmen 448000, Hubei, China

Abstract

Objective: To explore the clinical value of noninvasive positive pressure ventilation in COPD with acute respiratory failure.

Methods: The experimental group was treated with conventional therapy plus noninvasive positive pressure ventilation, whereas the control group was treated with conventional therapy combined with oxygen therapy. Before and after treatment, the clinical symptoms, respiratory rate, heart rate, blood gas, BNP, PCT and average length of stay were analysed.

Results: After treatment, the respiratory rate, heart rate, PaO2, PaCO2, SaO2 and pH of the patients in the experimental group and the control group were all improved, but the improvement range of the experimental group was significantly greater than that of the control group, and the average hospitalization time of the experimental group was significantly shorter than that of the control group (P<0.05). Compared with the control group, the BNP and PCT concentration in the experimental group improved significantly after treatment (P<0.05). Noninvasive positive pressure ventilation is more effective in the treatment of chronic obstructive pulmonary disease with acute respiratory failure. After treatment, there were significant improvements in patients’ monitoring indicators, which can effectively shorten the length of stay, and there were no adverse reactions.

Conclusion: This proves that noninvasive positive pressure ventilation has a good clinical application value in the treatment of chronic obstructive pulmonary disease with acute respiratory failure.

Keywords

Noninvasive positive pressure ventilation, chronic obstructive pulmonary disease, acute respiratory failure, clinical application value.

DOI:

10.19193/0393-6384_2022_3_264